The uptake of the once-every-six-month HIV prevention jab lenacapavir LEN in South Africa will be heavily affected by the Trump administrations funding cuts to the country, a new report has found.
South Africas first two shipments paid for with money from the Global Fund to Fight Aids, TB and Malaria arrived in late March and early April and roll-out is expected to start in late May to early June.
LEN is almost foolproof in stopping HIV-negative people from getting the virus through sex and scientists say if enough HIV-negative people take it, South Africa could end Aids by 2043.
Researchers conducted in-depth interviews with 40 participants such as doctors, nurses, peer counsellors, transgender people, young people, sex workers, gay and bisexual men and government health workers with personal experience of the funding cuts in Cape Town and Johannesburg.
Intodays newsletter,Mia Malan tells us more about thetricky road ahead for South Africas LEN roll-out.Sign up for our newsletter today.
South Africas uptake of the once-every-six-month HIV prevention jab, lenacapavir LEN, will be heavily affected by the Trump administrations funding cuts to the country, because it destroyed much of the infrastructure such as community-based testing and field recruitment for HIV prevention services needed to create demand for the medicine.
Thats one of the findings of a report released on Tuesday by the United States US-based organisation, Physicians for Human Rights, and two local nonprofits, Advocacy for the Prevention of HIV in Africa and Emthonjeni Counselling Training.
